Three months ago, the “Deno” company, the “quasi-unicorn” Hangzhou Denuo Electrophysiology Medical Technology Co., Ltd., was revealed by investors shareholders to have a shareholders' rights dispute with “anti-dilution rights and priority liquidation rights.” Recently, there have been new developments in this takeover case. The reporter learned from Zhang Mingfang, the former “first sister” of New Fortune Pharmaceuticals, that Denuo Electrophysiology will hold an extraordinary shareholders' meeting on July 29 to review the capital increase plan provided by Shanghai Chenyao Foundation and Yingtai Medical and a bill to amend the company's articles of association. Zhang Mingfang raised four questions about the content of the review of these two bills: First, the capital increase was a “preparatory action” made by the majority shareholders of the company to satisfy their own personal interests; second, the company's capital increase of 500 million yuan had already triggered the “anti-dilution rights” of the investor's minority shareholders; third, the company refused to provide shareholders, including Xinrui Yuanfu, with important information such as financial statements and audit reports; fourth, Yingtai Medical announced the acquisition of Deneul medical assets several times, and most of them achieved the withdrawal of actual controller shares. In response, attorney Wang Zhibin of Shanghai Minglun Law Firm told reporters that the company law clearly stipulates that shareholders have the right to inspect and copy financial accounting reports, and investment agreements also usually have specific agreements on this. In the context of the company's plan to increase capital and expand shares, financial information is an important basis for shareholders to exercise their voting rights, and the company should also guarantee shareholders' right to obtain relevant documents in a reasonable manner.

Three months ago, the “Deno” company, the “quasi-unicorn” Hangzhou Denuo Electrophysiology Medical Technology Co., Ltd., was revealed by investors shareholders to have a shareholders' rights dispute with “anti-dilution rights and priority liquidation rights.” Recently, there have been new developments in this takeover case. The reporter learned from Zhang Mingfang, the former “first sister” of New Fortune Pharmaceuticals, that Denuo Electrophysiology will hold an extraordinary shareholders' meeting on July 29 to review the capital increase plan provided by Shanghai Chenyao Foundation and Yingtai Medical and a bill to amend the company's articles of association. Zhang Mingfang raised four questions about the content of the review of these two bills: First, the capital increase was a “preparatory action” made by the majority shareholders of the company to satisfy their own personal interests; second, the company's capital increase of 500 million yuan had already triggered the “anti-dilution rights” of the investor's minority shareholders; third, the company refused to provide shareholders, including Xinrui Yuanfu, with important information such as financial statements and audit reports; fourth, Yingtai Medical announced the acquisition of Deneul medical assets several times, and most of them achieved the withdrawal of actual controller shares. In response, attorney Wang Zhibin of Shanghai Minglun Law Firm told reporters that the company law clearly stipulates that shareholders have the right to inspect and copy financial accounting reports, and investment agreements also usually have specific agreements on this. In the context of the company's plan to increase capital and expand shares, financial information is an important basis for shareholders to exercise their voting rights, and the company should also guarantee shareholders' right to obtain relevant documents in a reasonable manner.